Maraviroc news from FiercePharma
News
ALSO NOTED: Layoffs depress J&J profits; Canada OKs Pfizer HIV med;
> Pink slips cost money. Just ask Johnson & Johnson, which saw its third-quarter profits drop by 8 percent because of money spent cutting jobs. Read more...
ALSO NOTED: GSK to launch cervical cancer vaccine in EU;Ranbaxy licenses Sirtex cancer remedy;
> GlaxoSmithKline is now ready to launch its vaccine against cervical cancer, Cervarix, in the E.U--and analysts expect revenues of $2 billion to $5 billion there, based on rival Gardisil's Read more...
FDA: Merck's anti-HIV drug hopeful
Will the FDA give Merck a shovel to finish digging its public image out of the Vioxx pit? All set to meet next Wednesday on Merck's proposed HIV drug Isentress (raltegravir), the agency's Antiviral Read more...
Pfizer goes public with R&D pipeline
It's tough to take over the world when everyone can see your battle plans--or so thought Pfizer before CEO Jeffrey Kindler pledged transparency. Now the company's future can be viewed at its Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets